Calliditas Therapeutics AB

28.60+1.61+5.97%Vol 54.50K1Y Perf 45.41%
Apr 23rd, 2021 10:25 DELAYED
BID28.50 ASK28.66
Open28.45 Previous Close26.99
Pre-Market- After-Market-
 - -%  - -
Target Price
46.80 
Analyst Rating
— — 0.00
Potential %
64.04 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap714.17M 
Earnings Rating
Price Range Ratio 52W %
50.53 
Earnings Date
13th May 2021

Today's Price Range

28.2328.70

52W Range

19.0038.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.41%
1 Month
-9.94%
3 Months
-18.01%
6 Months
3.81%
1 Year
45.41%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CALT28.601.61005.97
AAPL133.101.16000.88
GOOG2 281.6413.72000.60
MSFT258.371.20000.47
XOM55.870.60001.09
WFC43.690.99002.32
JNJ164.69-0.4900-0.30
FB298.071.55000.52
GE13.540.13000.97
JPM149.321.95001.32
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.65-0.79-21.54
Q03 2020-0.39-0.62-58.97
Q02 2020-0.40-0.3122.50
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date13th May 2021
Estimated EPS Next Report-0.69
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume54.50K
Shares Outstanding24.97M
Trades Count426
Dollar Volume597.69K
Avg. Volume33.63K
Avg. Weekly Volume50.85K
Avg. Monthly Volume50.82K
Avg. Quarterly Volume37.29K

Calliditas Therapeutics AB (NASDAQ: CALT) stock closed at 26.99 per share at the end of the most recent trading day (a 1.28% change compared to the prior day closing price) with a volume of 90.65K shares and market capitalization of 714.17M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 34 people. Calliditas Therapeutics AB CEO is Renée Aguiar-Lucander.

The one-year performance of Calliditas Therapeutics AB stock is 45.41%, while year-to-date (YTD) performance is -19.72%. CALT stock has a five-year performance of %. Its 52-week range is between 19 and 38, which gives CALT stock a 52-week price range ratio of 50.53%

Calliditas Therapeutics AB currently has a PE ratio of -14.00, a price-to-book (PB) ratio of 4.78, a price-to-sale (PS) ratio of 14 101.80, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -37.43%, a ROC of -26.17% and a ROE of -44.10%. The company’s profit margin is -%, its EBITDA margin is -565.20%, and its revenue ttm is $47.65 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Calliditas Therapeutics AB, there were 1 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.69 for the next earnings report. Calliditas Therapeutics AB’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Calliditas Therapeutics AB is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Calliditas Therapeutics AB stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Calliditas Therapeutics AB has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Calliditas Therapeutics AB has a Sell technical analysis rating based on Technical Indicators (ADX : 8.31, ATR14 : 1.04, CCI20 : -43.39, Chaikin Money Flow : -0.27, MACD : -0.91, Money Flow Index : 54.71, ROC : -1.85, RSI : 46.55, STOCH (14,3) : 51.17, STOCH RSI : 1.00, UO : 46.13, Williams %R : -48.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Calliditas Therapeutics AB in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Calliditas Therapeutics AB

Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.

CEO: Renée Aguiar-Lucander

Telephone: +46 84113005

Address: Kungsbron 1, C8, Stockholm SE-111 22, , SE

Number of employees: 34

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

53%47%

Bearish Bullish

54%46%

News

Stocktwits